SK+F Oncology

SK+F Oncology, a specialized division of Eskayef Pharmaceuticals Limited, operates as a prominent entity within the pharmaceutical and healthcare sectors. Established in 2018, the organization focuses on the research, development, and manufacturing of high-quality anticancer therapeutics. By leveraging advanced pharmaceutical technologies and a robust manufacturing infrastructure, SK+F Oncology provides critical healthcare solutions designed to improve patient outcomes. The company maintains a workforce of 500-1,000 employees who are dedicated to ensuring the safety, efficacy, and affordability of their oncology product portfolio.

The firm operates from a single strategic location in Dhaka, Bangladesh, where it integrates skilled professional expertise with modern production standards. This operational footprint allows the company to maintain rigorous quality control protocols while scaling its capacity to meet the increasing demand for specialized cancer treatments. Meet SK+F Oncology's team to understand the leadership and technical expertise driving their mission to provide accessible oncology care to both local and international markets.

With an annual revenue of $22.1M, SK+F Oncology continues to expand its influence in the global healthcare landscape. The company remains committed to innovation in oncology, consistently investing in processes that enhance the delivery of life-extending medicines. By focusing on specialized therapeutic areas, the firm effectively positions itself as a key player in the pharmaceutical industry, prioritizing patient-centric care and sustainable growth through its dedicated oncology product line and strategic market initiatives.